CinCor Pharma IPO: How to buy the stock - All you need to know

Follow us on Google News:
 CinCor Pharma IPO: How to buy the stock - All you need to know
Image source: patpitchaya, Shutterstock

Highlights

  • CinCor Pharma plans to offer 11 million shares of its common stock in the IPO.

  • The expected price range of the offering is US$15 to US$17 per share.

  • It will offer an additional 1.65 million shares of its common stock to the underwriters.

Biopharmaceutical firm company CinCor Pharma, Inc. has filed for an initial public offering (IPO) with US Securities and Exchange Commission (SEC).

The Boston, Massachusetts-based firm filed the registration statement on Form S-1 on Monday.

It is developing a drug for cardiorenal diseases like hypertension. Its lead clinical candidate, CIN-17, is a highly selective oral small molecule inhibitor of aldosterone synthase, it said.

Also Read: US manufacturing PMI falls in December, factory activities up

What is in the offering?


According to the company's registration statement filed with the SEC, it plans to offer 11 million shares of its common stock to investors. The IPO price is expected to be between US$15 and US$17 per share. At this price range, the company is expected to raise US$187 million.

CinCor Pharma will offer all the shares of the common stock in the IPO. It will also provide an additional 30-day option for underwriters to purchase an additional 1.65 million shares of its common stock at the offering price, minus underwriting discounts and commissions.

The company plans to get listed on NASDAQ under the ticker symbol CINC.

The joint book-running managers for the IPO are Morgan Stanley, Jefferies, and Evercore ISI. Oppenheimer & Co. would act as the lead manager.

Also Read: Why is PancakeSwap (CAKE) token up today?

CinCor Pharma files for IPO with the SEC

Also Read: Why Keep Network (KEEP) crypto jumped over 12% today?


Financial Highlights of CinCor Pharma, Inc.

The company's total operating expenses were US$17.27 million for the nine months ended Sept 30, 2021, compared to US$15.61 million in the same period a year ago. Its net loss was US$21.02 million against a loss of US$16.48 million for the first nine months of 2020.

As of Sept 30, 2021, the company had cash and cash equivalents of US$141.70 million.

Also Read: Apple becomes first company to top US$3 trillion in market value

Bottomline

Healthcare companies are seeing massive opportunities in the market, spurred by a pandemic-fuelled demand. Scores of healthcare companies went public over the past year.

CinCor Pharma may value up to US$602.1 million after the IPO.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Featured Articles